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Abstract
New applications of evolutionary biology are transforming our understanding of
cancer. The articles in this special issue provide many specific examples, such as
microorganisms inducing cancers, the significance of within-tumor heterogene-
ity, and the possibility that lower dose chemotherapy may sometimes promote
longer survival. Underlying these specific advances is a large-scale transformation,
as cancer research incorporates evolutionary methods into its toolkit, and asks
new evolutionary questions about why we are vulnerable to cancer. Evolution
explains why cancer exists at all, how neoplasms grow, why cancer is remarkably
rare, and why it occurs despite powerful cancer suppression mechanisms. Cancer
exists because of somatic selection; mutations in somatic cells result in some
dividing faster than others, in some cases generating neoplasms. Neoplasms grow,
or do not, in complex cellular ecosystems. Cancer is relatively rare because of nat-
ural selection; our genomes were derived disproportionally from individuals with
effective mechanisms for suppressing cancer. Cancer occurs nonetheless for the
same six evolutionary reasons that explain why we remain vulnerable to other
diseases. These four principles—cancers evolve by somatic selection, neoplasms
grow in complex ecosystems, natural selection has shaped powerful cancer
defenses, and the limitations of those defenses have evolutionary explanations—
provide a foundation for understanding, preventing, and treating cancer.
Introduction
Our understanding of cancer is in the midst of a major
transition. Extraordinary recent progress in genetics and
cell biology is revealing details about cancer that under-
mine prior conceptions, and highlight the value of an evo-
lutionary perspective. The na€ıve notion that cancer is one
entity, with one cause, for which we can find a single cure,
is fading as the complex and dynamic nature of cancer is
becoming better understood (Gatenby 2009; Greaves and
Maley 2012). The emerging view recognizes cancers as het-
erogeneous collections of cells (Campbell et al. 2008; Park
et al. 2010; Maley et al. 2006; Merlo and Maley 2010) that
evolve in tumor microenvironments with complex ecolo-
gies (Bissell and Radisky 2001). A full understanding
requires evolutionary and ecological theory and methods.
The utility of evolutionary medicine (Nesse and Stearns
2008; Gluckman et al, 2009) for understanding cancer is
illustrated by four principles. The most obvious is that
neoplasms are heterogeneous populations of cells that
evolve via somatic evolution. This principle, and associ-
ated phylogenetic methods, is proving crucial to under-
standing tumor heterogeneity, and its significance for
optimizing chemotherapy. A second principle is that the
fitness of cells, like individuals, depends not only on their
genotypes and phenotypes, it also depends on their inter-
actions within complex ecosystems. Ecological theory is
proving important for understanding factors that stimu-
late and suppress the growth of neoplastic cells. The third
principle is that powerful defenses against cancer were
shaped by natural selection starting about one billion years
ago. Finally, evolutionary medicine (Nesse and Williams
1994) explains how the limits of these mechanisms arise
from the trade-offs between the risks of cancer and the
benefits of retaining dynamic tissue capacities for develop-
ment and repair.
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These four principles provide an evolutionary framework
for understanding the origins and progression of cancer
that is parallel to what the Hallmarks of Cancer framework
(Hanahan and Weinberg 2000) provides for understanding
cellular mechanisms involved in cancer. These perspectives
are entirely complementary; we need to know not only how
cell regulation mechanisms work but also how they evolved
to be the way they are, and why they are not better able to
protect us from disease.
Evolution explains how cancers arise from the differen-
tial survival and proliferation of mutant cells that promote
their own replication at the expense of the rest of the body
(Greaves and Kinlan 2000; Greaves and Maley 2012; Merlo
et al. 2006; Pepper et al. 2009). A view of cancers merely
growing is being replaced by recognition that they evolve
according to well-understood principles of somatic selec-
tion, along trajectories that can be described by established
methods for tracing phylogenies. This has practical applica-
tions for understanding the significance of heterogeneity
within tumors, and implications for diagnosis and treat-
ment.
Ecological theory is equally useful for understanding can-
cer progression and resistance to chemotherapy. The
growth, suppression, and death of neoplastic cells are
explained not only by their genotypes and phenotypes but
also by the microenvironments they inhabit. Such microen-
vironments impose powerful selection forces on neoplastic
cells, and those cells, in turn, induce changes in microenvi-
ronments. So, too, do chemotherapy treatments. No
amount of mechanistic detail is sufficient to explain these
interactions; ecological theory is crucial.
Natural selection shaped mechanisms that suppress can-
cer remarkably effectively. With about 60 trillion cells in
the human body, 500 billion of which are replaced each
day (Cooper and Hausman 2009), it is amazing we do not
all get cancer early in life. The relative rarity of cancer is
even more remarkable when you consider the diversity of
cells within many tumors, and the inevitability of somatic
selection increasing the prevalence of the most malignant
cells (Campbell et al. 2008; Park et al. 2010; Maley et al.
2006; Merlo and Maley 2010). The explanation goes back
to the most important ‘major transition’ in the history of
life—the origin of multicellular organisms about 1 billion
years ago (Maynard Smith and Szathmary 1995a). The ten-
sion between cell-level selection (somatic evolution) favor-
ing neoplastic cells, and organism-level selection
(organismal evolution) favoring individuals who are able
to suppress mutations and rouge cells, was central. As
organisms became longer lived, and the number of cells in
a body increased from hundreds to trillions, suppressing
cancer became ever more crucial (Caulin and Maley 2011;
Nunney this issue). In short, evolution at the organism
level shaped powerful mechanisms that suppress evolution
at the somatic level (see Fig. 1).
Why are not those mechanisms better? The six kinds of
evolutionary explanations for vulnerability to diseases in
general all apply to cancer (Nesse 2005; Williams and
Nesse, 1991). Evolutionary medicine attempts to under-
stand the reasons why the systems of the body are limited
in their capacities to protect us from disease. Nowhere is
this better illustrated than in the diverse reasons why we
remain vulnerable to cancer (Greaves 2007). As described
in greater depth in the final section of this paper (see Box
1), cancer vulnerability can be understood within the larger
framework of the six types of evolutionary explanations for
traits that leave organisms vulnerable to disease:
1 Mismatch with novel environments (e.g., tobacco avail-
ability? lung cancer)
2 Co-evolution with fast-evolving pathogens (e.g.,. HPV
? cervical cancer)
3 Constraints on what selection can do (e.g.,. mutations?
cancer)
4 Trade-offs (e.g.,. capacity for tissue repair versus risk of
cancer)
(A) (B)
Figure 1 Evolution explains why cancer exists and also why it is not more common. (A) Cancer results from somatic selection at the cell level that
favors neoplastic cells (red) over normal somatic cells (tan). (B) Cancer suppression results from selection at the organism level, favoring organisms
that have traits (e.g., DNA repair, cell cycle checkpoints/apoptosis, and certain tissue architectures), which keep neoplastic cells in check (blue) while
those individuals with traits that make them susceptible (pink) decrease in prevalence in the population.
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5 Reproductive success (RS) at the expense of health (e.g.,
cancer promoting alleles that may increase RS)
6 Defenses with costs as well as benefits (e.g.,. inflamma-
tion).
These four principles—somatic evolution of neoplasms,
ecological analysis of tumor environments, selection for
mechanisms that suppress cancer, and evolutionary expla-
nations for their limits—provide an evolutionary founda-
tion for understanding, preventing, and treating cancer.
Research making use of these principles is well underway,
but still at an early stage. The sections below illustrate the
opportunities and some directions forward.
Neoplasms evolve by somatic selection
Cancer cells are heterogeneous
Cancer is far from a single, well-defined disease. It is highly
diverse, in ways more subtle than the obvious differences
between cancers originating from different organs or tis-
sues. For example, subtypes of breast cancer each have dif-
ferent risk factors, different phenotypic and genotypic
characteristics, different effective treatment regimes, and
different recurrence risks (Althuis et al. 2004; Bauer et al.
2007; Beaber et al. 2008; Colditz et al. 2004; Dawood 2010;
Dolle et al. 2009; Foulkes et al. 2010; Koboldt et al. 2012).
New genetic evidence confirms that cancers are highly
diverse, even among cells within a single tumor. Genomics
and single cell analyses in a variety of cancers show dra-
matic heterogeneity among cells (Campbell et al. 2008;
Park et al. 2010; Maley et al. 2006; Merlo and Maley 2010;
Anderson et al. 2011; Navin et al. 2011; Gerlinger et al.
2012; Nik-Zainal et al. 2012). Some types of cancers are
characterized reliably by mutations in similar pathways or
identical genetic alterations, such as the BCR-ABL translo-
cation (Melo and Barnes 2007) or RB mutation in retino-
blastoma (Dyer and Bremner 2005), but even these cancers
can be highly diverse with regard to other mutations. Intra-
tumor heterogeneity is critical because it is the raw material
upon which somatic selection can act. Understanding can-
cers as intrinsically diverse is crucial because of the impor-
tance of heterogeneity in cancer progression and
therapeutic resistance (see Fig. 2) (Campbell et al. 2008;
Park et al. 2010; Maley et al. 2006; Merlo and Maley 2010).
Origins of heterogeneity
While much attention is focused on heterogeneity that
originated within neoplasms, theoretical calculations sug-
gest that many mutations important for cancer may occur
early in development, because a single early mutation may
be transmitted to thousands or millions of daughter cells in
a growing body (Frank 2010). This suggests that measures
of heterogeneity may predict vulnerability to cancer, the
need for close attention to the role of development in het-
erogeneity, and the importance of factors that influence the
fidelity of replication during early developmental stages
(Frank 2010; Meza et al. 2005).
Attention to development is equally important later in
life. For instance, rates of breast cancer rise sharply in mid-
life, but more slowly later (American Cancer Society 2012),
a pattern congruent with hormone induced cellular replica-
tion. However, similar patterns are found for other cancers,
leading to the challenge of differentiating several possible
explanations, including genetic heterogeneity (Frank
2007a).
Heterogeneity and cancer progression
Within-tumor heterogeneity has an important implication
for how somatic evolution proceeds: the more genetic vari-
ation in the population of cells, the more likely it is that
some variants will have proliferative or survival advantages.
Tumor diversity should therefore lead to faster progression
to cancer—which is indeed what is observed in Barrett’s
esophagus (Maley et al. 2006; Merlo et al. 2010). Further-
more, tumor diversity is associated with clinical variables
and histopathological characteristics associated with
aggressiveness in breast cancer (Park et al. 2010).
Therapy Relapse
resistant
sub-clone
Progression Resistance
Homogeneous
Heterogeneous
Therapy
Cure
Figure 2 Intra-tumor heterogeneity increases the likelihood that some mutants will have a proliferation or survival advantage, resulting in faster pro-
gression. Heterogeneity also increases the likelihood that there will be a resistant mutant already present in the cell populations before therapy, mak-
ing therapeutic resistance and relapse more likely.
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One of the primary causes of tumor heterogeneity is
genetic instability. Cancer cells exhibit a wide range of
genetic modifications, from point mutations to massive
chromosomal aberrations (Stephens et al. 2011). This
results in many non-functional mutant cells, but a few
whose genetic changes enhance their fitness. In Graham
et al. (this issue), a model of the evolution of genetic insta-
bility finds cancer cells readily evolving a mutator pheno-
type. The mutator phenotype is suppressed by the resulting
mutational load only under extreme parameters: where del-
eterious mutations are common, the cost of deleterious
mutations is prohibitively high, and the benefit for driver
mutations is extremely low. This surprising evolutionary
viability of the mutator phenotype echoes other findings
(Beckman and Loeb 2005) and is alarming given the carcin-
ogenic effects of genetic instability. A separate model found
that selection for driver mutations is more necessary for
tumor growth early in progression than during later stages
(Reiter et al. this issue).
Tumor heterogeneity is not only genetic; variations in
the environments that tumor cells inhabit may be equally
important. As is described in the next section on ecology,
cancer cells inhabit complex microenvironments that vary
substantially even within a tumor. For instance, Alfarouk
et al. (this issue) call attention to the differences in avail-
ability of resources for cells living close to blood vessels ver-
sus those living farther away. They propose that
heterogeneity in vascular density and blood flow are critical
factors promoting cell heterogeneity.
Heterogeneity and therapeutic resistance
Just as spraying fields with pesticides leads to selection for
resistant pests, chemotherapy selects for resistant cells.
Chemotherapy rarely kills every malignant cell. The
chemo-resistant cancer cells that survive are selected for,
and the chemo-sensitive cells are selected against. Hetero-
geneity of a tumor is therefore a likely to be a critical neg-
ative prognostic factor for chemotherapy outcomes,
especially considering the known role of genetic instability
in therapeutic resistance (Lee and Swanton 2012). After
chemotherapy, resistant cells are not only more prevalent,
they also have new ecological spaces into which they can
expand, with potentially disastrous implications for
patients.
Foo et al. (this issue) model tumor rebound growth fol-
lowing therapy and find that tumor diversity predicts early
relapse when mutation rates are high. This may reflect fas-
ter evolution in cell populations with more genetic varia-
tion, or it may reflect the degree of genetic instability in the
neoplasm. Because genetic instability is one of the primary
causes of heterogeneity, and because tumor heterogeneity
may increase genetically unstable variants, disentangling
the roles of heterogeneity and genetic instability in cancer
progression remains a major challenge. When mutation
rates are lower, early relapse is associated with differences
in the fitness of the sensitive and resistant cells rather than
the diversity of the cells. These findings make it clear that
the evolutionary processes underlying therapeutic resis-
tance and relapse are complex and cannot be described by
any simple generalization.
As discouraging as the seeming inevitability of the evolu-
tion of resistance might appear, considering evolutionary
dynamics is essential for finding strategies to reduce resis-
tance. For example, there is some evidence that lower dose
chemotherapy conditionally applied only when a tumor is
growing (the ‘adaptive therapy’ algorithm) leads to longer
survival than the traditional high dose chemotherapy in a
study of mice injected with ovarian cancer cells (Gatenby
et al. 2009). This may be because lower dose chemotherapy
does not select for chemo-resistant cells as strongly as high
dose chemotherapy does, and sensitive cells may have a fit-
ness advantage in the absence of therapy, leading to the
maintenance of tumor cells that are responsive to chemo-
therapy. Another potential contributor to the apparent suc-
cess of adaptive therapy may be that maintaining some of
the tumor decreases new ecological openings for resistant
cells to repopulate. In essence, adaptive therapy may pre-
vent rapidly dividing resistant cells from taking over the
population through a process analogous to ‘competitive
release’ in ecology (Williams 2010). Several studies on
adaptive therapy are currently in progress. If these efforts
succeed, the adaptive therapy strategy could offer substan-
tial clinical benefits.
Heterogeneity and homogeneity
Emphasis on the importance of tumor heterogeneity by no
means diminishes the importance of the continuing search
for factors common to most neoplasms. It is equally
important and unsurprising that mutations influencing cell
cycle checkpoints, angiogenesis, apoptosis, and telomere
synthesis are common across many neoplasms. The impor-
tance of heterogeneity also does not diminish the benefits
of looking for genetic signatures characteristic of tumors in
specific tissues, or signatures that define subtypes of cancers
within a tissue, such as has recently been accomplished for
breast cancer (Koboldt et al. 2012).
However, the search for shared factors and signatures
that define specific subtypes of cancer is already proceeding
at full speed. It seems to us that this effort to identify the
signature of specific types of cancer sometimes tends
toward essentializing types of cancer (see also Aktipis et al.,
2010), as if all cases in one category are expected to be the
same. In some respects they often are, and the classification
of a cancer can provide important guides to treatment.
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 144–159 147
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However, an evolutionary approach encourages viewing
variation among individuals, tumors, and cells as intrinsic
to the process that gives rise to cancer, and to life itself,
instead of as a limitation of our classification systems.
Implications of tumor heterogeneity
Somatic evolution can act only when cells have heritable
differences that influence survival or replication. Fisher’s
fundamental theorem of natural selection states that the
rate of increase in a population’s fitness is directly pro-
portional to its genetic variation in fitness (Fisher 1930).
The same principle applies to neoplasms; the more
genetic diversity, the faster it evolves via somatic selec-
tion. This means that tumor diversity should influence
cancer progression, not just for esophageal cancer, where
the link has already been established (Maley et al. 2006;
Merlo et al. 2010), but for all cancers. Further, heteroge-
neity is likely to emerge as a critical marker for resistance
to chemotherapy (Lee and Swanton 2012). Future clini-
cians might be able to customize treatment based on
tumor heterogeneity. As compared with traditional high
dose chemotherapy, the adaptive therapy algorithm may
extend survival over traditional high dose therapy, espe-
cially when tumors are highly heterogeneous and there-
fore likely to already harbor resistance mutations. Other
strategies will also emerge from deeper understanding of
somatic selection of heterogeneous cells.
Cancers evolve in ecological contexts
Overview of cancer ecology
The environments in which cancer cells live and evolve is as
complex and multifaceted as the environments in which
organisms evolve. The life of a cell in the body is character-
ized by complex development in a shifting ecosystem, fol-
lowed by exposure to a variety of threats and opportunities,
including attack by predatory immune cells, the limited
availability of resources such as growth factors, oxygen, and
glucose, and physical constraints and affordances shaped by
adjacent cells and the basement membranes to which they
are attached. Finally, many somatic cells live and evolve in
environments teeming with diverse fast-evolving microbes.
Taken together, these environmental and ‘social’ factors
create a complex ecology that influences the fitness of
somatic cells (Fig. 3) (Gatenby and Gillies 2008; Pienta
et al. 2008). Indeed, the normal microenvironment of cells
plays a critical role in cancer suppression, and changes to
that microenvironment are a key factor in cancer initiation,
progression and response to treatment (Correia and Bissell
2012; Nakasone et al. 2012; Pontiggia et al. 2012; Bissell
and Hines 2011; Bissell and Radisky 2001).
The central roles of tumormicroenvironment in suppress-
ing and promoting cancer make ecological theory an essen-
tial tool for cancer researchers, as illustrated by four papers
on the topic in this special issue (Thomas et al. this issue;
Ewald and Swain Ewald this issue; Daoust et al. this issue;
Cell Ecology Organism Ecology
resource
delivery
resource
delivery
regulation of
growth and survival
dependence for
survival and reproduction
immune
predation
predation
diverse microbes diverse species
Figure 3 The ecological context of cancer cells parallels the ecological context for organisms. Similarities include dependence on limited resources,
dependence on neighbors for survival and reproduction, interactions with other species and threats from predation. In the case of cancer cells, their
ecological context is characterized by dependence resource delivery from blood vessels, growth and survival signals from neighbors, interactions with
microbial species and predation from the immune system. Similarly, the ecological context for organisms is characterized by dependent on resource
delivery from the environment, dependence on neighbors for effective survival and reproduction, interactions with other species and threats from
predators.
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Alfarouk et al. this issue). Daoust et al. (this issue) describe
applications of landscape ecology to cancer, offering
methods for identifying tissue microhabitats that influence
tissue growth, and vulnerability to metastasis. Similarly,
Alfarouk et al. (this issue) describe how cells evolving near
blood vessels (and their associated resources) are expected to
evolve differently than those distant from blood vessels.
Neighboring cells
The world of cancer cells is highly social. Tumor microenvi-
ronments include both other tumor cells as well as ‘normal’
cells nearby. These normal cells can be co-opted to provide
growth signals or other fitness enhancing factors for the
cancer cells. It remains known, for example, that the risk of
cancer can be increased by a variety of changes to neighbor-
ing support cells or stroma (a combination of fibroblasts,
vasculature, immune cells, and interstitial extracellular
matrix) (Bissell and Hines 2011). Fellow cancer cells may
also provide growth factors or engage in other actions that
enhance their neighbor’s fitness (Axelrod et al. 2006).
One paper in this issue (Sprouffske et al. this issue)
argues that the maintenance of ‘non-stem cells’ in the
tumor cell population may be explained by the positive
influence of these cells on the fitness of genetically identical
tumor-propagating cells (‘stem cells’). In other words, the
model suggests that ‘non-stem cells’ could play a similar
evolutionary role to ‘helpers at the nest’ in cooperative
breeders (Alcock 2009), promoting their fitness indirectly
through enhancing the fitness of their genetically identical
parent ‘stem cell.’ The authors suggest that the promotion
of tumor-propagating cells (‘stem cells’) by ‘non-stem cells’
may be similar to the promotion of the germ line by
somatic cells in multicellular organisms. The importance of
‘stem cells’ or tumor-propagating cells for cancer progres-
sion is the focus of Greaves (Greaves this issue), who calls
attention to the fact that stem cells are the unit of selection
in cancer, an observation supported by the results of
Sprouffske et al.’s (this issue) model.
The role that neighboring cells can have on each others’
fitness also has implications for drug targeting. Drugs that
disrupt the actions of secreted factors that benefit nearby
cells (i.e., public goods) might slow development of thera-
peutic resistance to chemotherapeutic agents (Pepper
2012). Although cytotoxic drugs exert strong selection for
cells that are resistant to therapy by killing as many cancer
cells as possible, drugs that target public goods should not
select strongly for resistant cells (Pepper 2012).
Resource use and availability
Resource availability for a cell is influenced by both its own
characteristics and by interactions with neighboring cells.
For example, cancer cells that coordinate and regulate
angiogenic signaling (for blood vessel growth) may induce
greater blood flow to the tumor. Cells that do not coordi-
nate angiogenic signaling may induce leaky vessels that
temporarily increase blood flow (Nagy et al. 2012) until
vessels collapse because of pressure loss resulting from
excess permeability.
Some of these interactions among cells mimic character-
istics of resource dilemmas in human populations, such as
the Tragedy of the Commons (Hardin 1968), and can be
profitably analyzed using game theory (Axelrod et al.
2006). Dilemmas such as these are characterized by conflict
between individuals pursuing their own interests versus the
interests of the group. Such dilemmas have important con-
sequences for tumor evolution. For example, some models
suggest that competition among cancer cells resulting in
resource overuse may contribute to invasion and metasta-
sis, just as high rates of resource use lead to dispersal of
organisms (Aktipis et al. 2011). More generally, resource
availability and distribution are expected to speed the evo-
lution of cell motility in ways analogous to those observed
for species (Chen et al. 2011). More subtle factors, such as
the carrying capacity of the microhabitat, the quality of that
habitat, and habitat fragmentation, also impose important
selection forces that shape cancer cells (Daoust et al. this
issue).
Predation by immune cells
Organisms evolve capacities for evading their predators.
Predators, in turn, evolve strategies for catching their prey
despite all attempts at evasion. The resulting co-evolution
shapes traits that can be understood only in light of their
evolutionary histories. Somatic cells exposed to the threat
of predation by immune cells vary in their ability to evade
the immune system. Those that succeed best have a selec-
tive advantage, and they proliferate at the expense of others
(Crespi and Summers 2005). This co-evolutionary process
is ongoing in most cancers. Strategies malignant cells
evolve for evading the immune system include mimicry,
hiding, and co-opting immune cells in ways that speed can-
cer growth. (Gabrilovich and Pisarev 2003; Cavallo et al.
2011).
Co-evolution with microbes
Cancer cells also co-evolve with cells from other species,
namely the microbes that make up the microbiome.
Human microbiome cells outnumber somatic cells 10 to 1
(Peterson et al. 2009). They are highly diverse, both among
individuals and within a particular individual (Eckburg
et al. 2005). Interactions with these microbes may, via
somatic evolution, increase cancer vulnerability. The pres-
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 144–159 149
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ence of certain microbes is associated with specific cancers
including colorectal, gastric, oral/esophageal, mammary,
lung, liver, and blood cancers (as reviewed by Arthur and
Jobin 2011), suggesting that they may play important roles
in cancer initiation and progression. The mechanisms
underlying microbial influences on cancer are just starting
to be understood, but it is clear that altered metabolism
and immune system functions are important. It has long
been known that inflammation increases susceptibility to
cancer (Grivennikov et al. 2010), but recent work in mice
suggests that bacterial colonization in distant tissues can
alter gene expression elsewhere in the body, causing meta-
bolic changes and inflammation in uninfected tissues (Rog-
ers 2011). Microbes can also induce cells to switch from a
stationary epithelial phenotype to a mobile mesenchymal
phenotype called the Epithelial-Mesenchymal Transition
(EMT) since microbes produce a variety of factors that can
have effects on signaling pathways leading to EMT (Hof-
man and Vouret-Craviari 2012). This may have important
implications for the transition from benign neoplasm to
invasive and metastatic cancer.
Exploitation by other species
Microbes can also influence neoplastic growth. One of the
body’s main defenses is mechanisms that kill infected cells,
so it is not surprising that viruses can promote their own
fitness through interfering with cell cycle arrest, apoptosis,
telomere regulation, and cell adhesion (Ewald and Swain
Ewald this issue). Such phenomena may explain how
microbes can induce cancer. Cancer vulnerability should be
increased by microbes that enhance their own fitness by
increasing the proliferation of somatic cells that provide
growth factors, immune protection, or physical niches in
which the microbes thrive. In other words, while cancer
may result from inflammation induced by microbes, it can
also result from microbes increasing their own fitness by
inducing somatic cell proliferation.
Crypts in the gastrointestinal tract provide niches for gut
microbes, many of which are commensal and promote nor-
mal gut functioning (Yu et al. 2012). This raises the possi-
bility that some cancers could result from side effects of
mechanisms that microbes use to induce niche formation
and expansion. Crypts produce mucus (Takubo et al. 1995;
Levine et al. 1989) that promotes the survival of certain
bacteria (Van den Abbeele et al. 2012; Hansson 2012), and
colorectal adenomas are associated with mucosal adherent
bacteria characterized by higher diversity (Shen et al.
2010), suggesting complex interactions between the cells
that line crypts, and the bacteria that colonize the resulting
niches.
This possibility might also be involved in Barrett’s
Esophagus, a premalignant condition characterized by the
formation of crypts in the esophagus, where they are not
normally present. During the process of neoplastic trans-
formation, these crypts become longer and more tortuous
(Srivastava et al. 2007). The formation of these crypts, and
their subsequent lengthening, could result from microbes
manipulating cell proliferation in ways that construct larger
and more plentiful mucus-producing niches that benefit
them, despite increasing cancer susceptibility for their host.
Several findings support these speculative ideas, including
(1) the association of esophageal cancer with specific
microbes (Yang et al. 2009), (2) shorter crypts in germ free
animals (Yu et al. 2012), and (3) longer crypts after oral
inoculation with bacteria (Yu et al. 2012).
Species extinction and cancer regression
Ecological theories describing species extinctions have
implications for treating and preventing cancer. All indi-
viduals have neoplastic clusters of cells, most of which will
never progress to cancer. Sometimes these growths sponta-
neously regress, a process analogous to species extinction.
Tumor regression after treatment is also akin to extinction.
Though treatment may cause regression, observations of
spontaneous regression in the absence of treatment suggest
that other mechanisms may also result in extinction of a
malignant cell lineage. Applying ecological theories about
species extinction to understanding why cancer cells regress
(either spontaneously or as the result of treatment), sug-
gests close attention to processes such as habitat destruc-
tion (Kareva 2011), competition, resource limitation, and
factors that disrupt reproduction. Anti-angiogenic therapy
limits blood supply to tumors, but has yielded mixed
results, perhaps because the decrease in resource availability
may select for dispersal or cell motility (Aktipis et al.
2012). Indeed, anti-angiogenic therapy may increase rates
of metastasis (as reviewed in Grepin and Pages 2010). A
more thorough ecological approach may help researchers
anticipate these sorts of consequences and limit unintended
negative effects.
Implications of ecological theory for cancer research
Ecological theory offers tools and perspectives that help
make sense of the complexities of cancer. Closer attention
to the environment in which cancer evolves may suggest
ways to slow cancer progression, enhance the effectiveness
of treatment, or otherwise prolong life. These approaches
include limiting the availability of resources for cancer cells,
altering the social signals and context of neoplastic cells,
and shaping interactions with microbes in ways that limit
the fitness of neoplastic cells. They are parallel to
approaches for understanding and limiting the abilities of
pathogens to establish niches that allow them preferential
© 2012 The Authors. Published by Blackwell Publishing Ltd 6 (2013) 144–159150
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access to resources (such as oxygen and glucose) and pro-
tection from threats (such as circulating immune cells). In
the gastrointestinal tract “especially” perspectives from
ecology, evolution, and microbiology intersect in ways with
profound implications for understanding, preventing, and
treating cancer.
Organism-level evolution shapes cancer
suppression
Overview of cancer suppression
The story of cancer begins about one billion years ago at
the dawn of multicellularity. Before the transition to meta-
zoans, natural selection shaped one-celled organisms for
whatever traits maximized their representation in future
generations, especially maximal proliferation, invasion of
adjacent spaces, and transmission to open niches. The
transformation from unicellular to multicellular life was
possible only when cells that cooperated by inhibiting their
replication gained a selective advantage over those that
went it alone (Maynard Smith and Szathmary 1995b). How
can cells that sacrifice their own capacity for replication
succeed in competition with ‘selfish’ individual cells? Socie-
ties of cooperative cells can outcompete cells that try to go
it alone. The success of these societies depends on their
ability to suppress or kill cells that do not cooperate (Nun-
ney this issue). This explains the evolution of the many
mechanisms that suppress cancer, including effective DNA
repair, cell cycle checkpoints, apoptosis, epigenetic modifi-
cations, and tissue architectures that limit the ability of
over-proliferative cells to expand widely (Gatenby et al.
2010). Similarly, Ewald and Swain Ewald (this issue) argue
that evolution has acted on multicellular organisms to cre-
ate five primary barriers to the evolution of metastatic can-
cer: cell cycle arrest, apoptosis, limits to the number of cell
divisions, cell adhesion, and asymmetric cell division. Can-
cer suppression mechanisms like these make it less likely
that benign neoplasms will progress to cancer. In other
words, evolution not only explains why cancer exists, it also
explains why cancer is remarkably rare.
The transition to multicellularity
Prior to the multicellular transition, mechanisms for inhib-
iting cell division were useless, with one crucial exception.
In harsh environments, attempts to replicate are wasteful
and may even kill a cell, so cells that can inhibit replication
in these circumstances get a selective advantage. These
mechanisms may have been co-opted in the transition to
metazoan life, to regulate cell division during development,
and to prevent cancer. This is consistent with genetic evi-
dence for the continuity of mechanisms for programmed
cell death from unicellular organisms to large multicellular
organisms (Nedelcu 2009). During that transition, cancer
suppression must have been a powerful selection force.
Individuals with cells that divided out of control were at a
severe selective disadvantage compared with those capable
of controlling cell division and suppressing cancer to create
functional multicellular bodies. The trade-offs between
cancer suppression and functional multicellularity are cen-
tral, not only to understanding cancer but understanding
multicellular life itself.
Peto’s paradox and body size
Building complex multicellular organisms in the face of
somatic evolution of cells in the body involves a multitude
of trade-offs. As organisms became larger, longer lived,
with orders of magnitude more cells, suppressing cancer
became a larger problem. If we assume that every cell in a
multicellular body has a certain chance of becoming malig-
nant every year, then large, long-lived animals like ele-
phants should have vastly higher rates of cancer than mice.
However, this is not what we observe: large, long-lived ani-
mals seem to have similar (or lower) rates of cancer than
small, shorter lived animals (Caulin and Maley 2011). This
apparent inconsistency is known as Peto’s paradox. What
explains the unexpectedly low rate of cancer in large ani-
mals? Cancer itself has been a selection force that has
shaped cancer suppression mechanisms that are as effective
as they need to be, whatever the size of the organism.
Indeed, emerging evidence suggests that, at least in the case
of elephants, large animals may have more copies of tumor
suppressor genes (Caulin and Maley 2011). Consistent with
these findings, Roche et al. (this issue) describe a model
showing that tumor suppressor genes are more likely to be
activated more in animals with large body sizes. There are
other possible explanations for Peto’s paradox including
the possibility that slower metabolic rates of larger organ-
isms are protective (Caulin and Maley 2011). Investigations
of Peto’s paradox illustrate the power of the comparative
method in evolutionary medicine.
Interestingly, if we look within species, size does influ-
ence cancer incidence. Tall humans are at significantly
greater risk for cancer than shorter humans, with a 10 cm
height increase leading to a relative risk of 1.1 for males
and 1.14 for females. The same pattern holds for other spe-
cies, such as dogs and rodents (as reviewed by Nunney this
issue). This suggests that, within a species, large size should
be correlated with cancer risk, but that among species can-
cer risks should be relatively similar because selection has
shaped cancer suppression mechanisms including include
DNA repair, immune surveillance, cell cycle checkpoint
genes (such as p53), specialized tissue architecture, apopto-
sis, contact inhibition, and telomere length at the species
level. As expected, small and large organisms differ in a
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Text Box 1. Evolutionary Reasons for Disease Vulnerability Applied to Cancer
Despite millions of years of evolution of cancer suppression mechanisms, we remain vulnerable to cancer. Nesse and Williams (Nesse
2005; Nesse and Williams 1994) offer six main reasons why natural selection leaves bodies vulnerable to disease (numbered below).
Vulnerability to cancer can be understood within this same framework (bullets underneath numbers):
1 Mismatch with the modern environment: Selection is too slow to adapt bodies to rapidly changing environments,
especially changes induced by human cultures.
• Population migration and skin cancer (Jablonski and Chaplin 2010)
• Caloric availability and obesity as a cancer risk factor (Wolin et al. 2010)
• Higher availability of fats that promote tumor growth (Sauer et al. 2005)
• Tobacco availability and smoking as a cancer risk factor (Peto et al. 2000)
• Differences in number of reproductive cycles and breast cancer (Coe and Steadman 1995; Strassmann 1999;
Eaton et al. 1994)
• Exposure to light at night may increase breast cancer risk (Tomlinson et al. 2007; Blask et al. 2005).
2 Co-evolution with pathogens: Pathogens evolve much faster than larger organisms can, and co-evolution of patho-
gens and their hosts shapes extremely expensive and dangerous defenses.
• The presence of specific microbes is associated with several specific cancers (as reviewed by Arthur and Jobin
2011)
• Viruses induce some cancers (Ewald and Swain Ewald this issue)
• Viruses integrated into our genome may influence cancer susceptibility (Tooby 2011)
3 Constraints on selection: Constraints on what natural selection can do are severe, including both limitations of space
and time that apply to all systems, and the inability to start with a fresh design that limits organic but not mechanical
systems.
• Path-dependence in highly conserved cell cycle control mechanisms (Hartwell and Kastan 1994) may leave
organisms susceptible to cancer or constrain therapeutic options
• Constraints on the immune system’s ability to detect cancer cells (Mapara and Sykes 2004) because cancer cells
are derived from normal cells
4 Trade-offs: Changes that would make a trait less vulnerable to disease often lead to a decrease in fitness due to effects
on other traits.
• Fast and effective wound healing requires cell movement and proliferation (Guo and Dipietro 2010), capacities
that leave an organism more vulnerable to cancer (Hofman and Vouret-Craviari 2012)
• Fast growth may come at the cost of somatic maintenance, leading to cancer vulnerability (De Stavola et al.
2004)
5 Reproduction at the cost of health: Bodies are not shaped by natural selection for health or longevity; they are shaped
to maximize reproductive success.
• Competitiveness in males may lead to higher susceptibility to prostate cancer (Calistro Alvarado this issue)
• Early menarche comes at the cost of higher susceptibility to breast cancer in females (Hsieh et al. 1990)
• Women with BRCA mutations have greater susceptibility to breast cancer but also higher fertility (Smith et al.
2011)
6 Evolved capacities for defense and their costs:Many of the problems people bring to their physicians are not diseases
themselves, but protective defenses shaped by natural selection such as cough, fever, pain, and vomiting. Like every-
thing else, they have costs.
• The capacity for inflammation is crucial not only for defending against infection but also for dealing with rouge
cells. However, inflammation also damages tissues and makes them more vulnerable to cancer (Coussens and
Werb 2002; de Visser et al. 2006).
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variety of these mechanisms (as reviewed by Caulin and
Maley 2011).
Evolutionary explanations for cancer vulnerability
The story of the evolutionary origins of cancer and cancer
suppression mechanisms is mostly one of selection and con-
straints. Cancer exists because cells were originally shaped
to maximize replication. Cancer is rare because selection at
the individual level has shaped powerful mechanisms to
suppress cancer. The crucial remaining question is, why are
not those mechanisms better? One major reason why cancer
cannot be perfectly suppressed is that natural selection has
constraints (see also Greaves 2007). Mutations happen, and
path-dependence means that fundamental design limita-
tions, such as the blind spot in the vertebrate eye, can never
be corrected.
What about the other 5 evolutionary explanations for
vulnerability to disease? (see Box 1) All of them contribute
to explaining our vulnerability to cancer. Co-evolution
with fast-evolving pathogens has already been discussed,
with special emphasis on the benefits pathogens can get by
inducing host cell replication. Closely related are defenses
shaped by natural selection that contribute to cancer, espe-
cially the capacity for inflammation, with its unavoidable
associated tissue damage. That leaves mismatch with mod-
ern environments and trade-offs, including the special
trade-off of reproductive success at the expense of health.
Mismatch
Cancer is not a disease exclusively of modern environ-
ments. Evidence for cancer in ancient mummies (Nerlich
et al. 2006; David and Zimmerman 2010), to say nothing
of other species, makes it obvious that cancer is not evolu-
tionarily novel. Some kinds of cancer are, however, more
common now than in ancestral times, often for obvious
reasons. Lung and throat cancers increase dramatically in
populations where smoking spreads, and decrease where
smoking is curtailed (Peto et al. 2000). Mismatch between
ancestral conditions and modern environments can also
increase cancer rates when subpopulations move to envi-
ronments different from those in which their ancestors
evolved. Melanin pigmentation is a defense against skin
damage, cancer, and perhaps degradation of folic acid as
well. However, deeply pigmented skin also limits vitamin-
D biosynthesis in environments with lower sun exposure.
This is the leading explanation for the evolution of depig-
mented skin outside of the tropics (as reviewed by Jablon-
ski 2004). The migration of light-skinned individuals to
equatorial zones results in a mismatch between skin pig-
ment and sun exposure that explains high rates of skin can-
cer.
More intriguing are increases in cancer rates arising
in association with changes in reproductive patterns.
Breast cancer rates are estimated to be more than ten
times higher for women in the USA compared with
hunter-gatherers (Eaton et al. 1994). This seems likely
to result from increased hormone exposure, starting
with earlier menarche, then augmented by contracep-
tion and years spent in reproductive cycles that would
previously have been spent nursing babies. The average
woman in the USA has over 400 menstrual cycles,
compared with 100 in women in a pastoralist culture
in Africa without birth control (Strassmann 1999). The
role of hormone levels is supported further by a com-
parative study showing a high correlation between
breast cancer rates and average levels of progesterone
(Jasienska and Thune 2001).
When considering all cancers, the role of mismatch with
modern environments is overwhelming. About one-third
of cancers are direct complications of tobacco use, and
another third are reported to be results of obesity, inactivity
or poor diet (American Cancer Society 2012). In addition,
many cancers are caused by radiation, hormone treatments,
environmental exposures, and new pathogens. In contrast,
only about 5% of cancers are products of hereditary genetic
abnormalities. Cancer in modern populations is caused
mainly not by the innate inadequacies of our bodies, but by
exposure to aspects of modern environments for which our
bodies are ill prepared.
Another important contributor to cancer rates in the
modern environments is vastly extended average life span
resulting from general good health and nutrition, and
protection from infection. Hunter-gatherers who reach
adulthood are very likely to live into their 60s or 70s, but
prevention of early death has increased the average life-
span in modern societies by decades, and the proportion
of people over 60 is many times larger than ever before.
Cancer increases with age, as there are increased numbers
of cell divisions, more accumulation of somatic muta-
tions, and declining abilities to suppress cancer (Cancer
Research UK 2012; American Cancer Society 2012). Some
think that selection can have no effect after reproduction
ceases, but this is incorrect; actions at any age that benefit
kin who share your genes can influence an individual’s
contributions to the future gene pool. Nonetheless, the
force of selection declines steeply starting at the age of
first reproduction simply because some individuals die
each year, even in the absence of aging and cancer. As a
result, selection for mechanisms that suppress cancer fades
to nearly nothing at advanced stages of life. As with can-
cer in general, the amazing thing is that the suppression
mechanisms continue to work as well as they do at
advanced ages.
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Trade-offs
Trade-offs are at the very center of evolutionary thinking.
This is nowhere more evident than in applications to can-
cer. Organisms could have better mechanisms to prevent
cancer, but the costs might be high for wound healing,
growth, reproduction, and aging.
A key trade-off for any organism is between limiting
uncontrolled cell division while maintaining the capacity to
repair tissues. To heal a wound, cells must be able to prolif-
erate and move (Guo and Dipietro 2010). However, having
cells with the capacity to proliferate and move leaves an
organism more vulnerable to cancer (Hofman and Vouret-
Craviari 2012). Wound healing also requires the rapid gen-
eration of new blood vessels to nourish and oxygenate the
healing cells (Guo and Dipietro 2010). Given that angio-
genesis is one of the hallmarks of cancer (Hanahan and
Weinberg 2000), the capacity for rapid angiogenesis is
likely to increase vulnerability to cancer, despite its func-
tion in wound healing.
The trade-off between wound healing capacity and can-
cer suppression offers an important area for further work.
In species that encounter greater physical threats (whether
from high rates of injury from predators or high rates of
intra-species aggression), one might expect that fast and
effective wound healing to be a relatively stronger selective
pressure than cancer suppression. Within a species, indi-
viduals with faster wound healing may be more vulnerable
to cancer. Even within individuals, exposure to injuries or
physical threats could conceivably shift physiological sys-
tems toward faster wound healing despite the increased risk
of cancer. This hypothesis predicts that variations in the
prevalence of injury among species (and perhaps among
individuals within a species) may be associated with faster
wound healing and higher cancer risk. These admittedly
speculative suggestions can be tested using the comparative
method, and they gain some support from evidence that
aggression is associated with cancer risk in fish (Fernandez
2010), and that aggression may be associated with faster
wound healing in baboons (Archie et al. 2012).
Embryogenesis and development are essential to multi-
cellularity, but the cell capacities associated with these
functions leave individuals vulnerable to cancer. Develop-
ment involves ‘invasion’ of cells into other developing
tissues during gastrulation. The capacity to transition
from a stationary epithelial cell to a motile mesenchymal
cell (a process known as the Epithelial-Mesenchymal
Transition or EMT) is crucial to this process, but leaves
organisms vulnerable to cancer (Hofman and Vouret-
Craviari 2012).
Fast body growth and sexual maturation also increase
cancer susceptibility. If replication is more accurate in
slower growing organisms, they should have lower risks of
cancer. The possibility that mutations early in development
are especially important influences on cancer risk makes
this doubly interesting (Frank 2007b). However, slower
growth means…slower growth, thus delaying reproduction
and reducing fitness. The advantages of faster growth may
also have trade-offs resulting in increased risk of cancer
because of less DNA repair, less apoptosis of cells with DNA
damage, more generation of mutations earlier in develop-
ment and perhaps higher levels of receptors for growth fac-
tors. This may explain why rates of breast cancer are higher
for those with faster childhood growth (De Stavola et al.
2004), and early menarche (Hsieh et al. 1990), although
increased hormone exposure may contribute as well.
Trade-offs between cancer and aging are illustrated by a
tumor suppressor gene, p53 (TP53). Mice with supernu-
merary copies of p53 are protected from cancer, likely
because they exhibit an enhanced response to DNA damage
(Garcia-Cao et al. 2002). However, if the extra copies are
constitutively expressed, mice show signs of premature
aging (Tyner et al. 2002). If p53 is placed under proper reg-
ulatory control by its endogenous promoters, these super
p53 mice do not age prematurely (Garcia-Cao et al. 2002),
suggesting that aging and cancer are fitness trade-offs that
have shaped the mechanisms that activate p53.
Reproductive success at the expense of health
It is disturbing to recognize that natural selection does not
shape organisms directly for health or longevity. An allele
that increases net reproductive success will tend to increase
in frequency irrespective of its effect on health. This phe-
nomenon is most evident in the higher mortality rates in
men compared with women in most modern societies. Suc-
cess in mating competition has greater reproductive payoffs
for males in many species, so natural selection has shaped
investment in competitive abilities that are proportionately
greater than investment in tissue repair capacities, as com-
pared with women (Kruger and Nesse 2006). In developed
societies, this results in early adult mortality rates three
times higher for men than women.
The role of testosterone is evident in the correlation
between testosterone levels and risk of prostate cancer. In a
sophisticated analysis examining various factors contribut-
ing to epidemiological differences among human sub-
groups and rates of prostate cancer, Alvarado (this issue)
notes that high levels of nutrition in modern Western cul-
tures increases both investment in mate competition and
testosterone levels. Subpopulations where competition is
especially physical and desperate have higher testosterone
levels and increased mating success, but at the cost of
increased rates of prostate cancer. This thesis receives sup-
port from comparative studies showing higher rates of
prostate cancer in human polygamous societies compared
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with monogamous cultures living adjacent in similar cir-
cumstances in Africa (Calistro Alvarado this issue). Trade-
offs of this sort may exist for female susceptibility to breast
cancer as well, as estrogen response to competitive interac-
tions is associated with higher motivation for power (Stan-
ton and Schultheiss 2007).
Many of the examples above fit neatly into evolution-
ary life history theory and its analysis of the trade-offs
between somatic maintenance (i.e., acquiring resources
and keeping one’s body running in tip-top shape) and
reproductive effort (i.e., acquiring mates, and making
and caring for offspring) (Stearns 2000). In environments
with high levels of extrinsic mortality, selection favors
investment in early reproduction at the expense of
somatic maintenance. Furthermore, environmental cues
can calibrate these systems as a function of early experi-
ence or current conditions. Threats and uncertainty may
shift investment from long-term reproductive goals to
immediate survival goals, including up-regulation of the
immune system and inflammation, more investment in
wound healing, and speeding growth and reproductive
maturity, even at the cost of higher long-term cancer
risk. The life history trade-offs involved in differences in
prostate cancer risk across populations noted by Alvarado
(this issue) are a good example. For women, similar
trade-offs may help to explain increased rates of breast
cancer risk after exposure to stressful experiences, such as
war exposure early in life (Keinan-Boker et al. 2009; Elias
et al. 2004; Koupil et al. 2009). In mice, the stress of
early social isolation leads to higher mammary cancer
burden (Williams et al. 2009) and faster reproductive
aging (Hermes and McClintock 2008).
Implications of selection for cancer suppression, and its
limits
Cancer suppression is as ancient as multicellular life. Multi-
cellular organisms must have mechanisms to suppress can-
cer effectively. As evolution shaped larger and longer lived
species, the problem of cancer suppression became more
challenging, and the solutions for suppressing cancer
became remarkably effective. They can never be perfect,
however, for the same six evolutionary reasons that other
bodily traits remain vulnerable to disease.
Conclusion
The benefits of using evolutionary principles to understand
cancer provide a specific example of the benefits of evolu-
tionary medicine more generally. An evolutionary approach
can help us understand why cancer exists and how it pro-
gresses (somatic evolution), how cancer cells interact with
environments (ecological approaches), why it is not more
common (natural selection for cancer suppression mecha-
nisms), and why cancer suppression mechanisms can never
be perfect (constraints, trade-offs, and other evolutionary
reasons for vulnerability to disease). Evolution is essential
for understanding cancer. It provides a framework for
studying the evolutionary origins and progression of cancer
that is parallel and complementary to the Hallmarks of
Cancer framework for studying the mechanisms of cancer.
The importance of an evolutionary understanding cancer
is not just an academic pursuit; it has great clinical utility
that remains largely untapped. Evolutionary theory and
methods have led to critical advances that promise to
improve how we understand and treat cancer. For example,
the finding that diversity in the premalignant biopsies pre-
dicts progression to cancer (Maley et al. 2006; Merlo et al.
2010) suggests methods for risk stratification, and a focus
of clinical resources on those patients with the highest like-
lihood of cancer progression. Also, the development of
novel therapeutic approaches, such as Gatenby’s adaptive
therapy algorithm (Gatenby et al. 2009), holds the promise
of revolutionizing the way some cancers are treated—shift-
ing the focus from eliminating every cancer cell, to control-
ling cancer by manipulating selection forces within the
tumor. An evolutionary analysis of chemotherapy resis-
tance suggests that taking another biopsy after a relapse
may identify resistant mutations and guide targeted second
line therapies. Finally, a clearer understanding of how large
organisms suppress cancer (Caulin and Maley 2011), and
the trade-offs inherent in cancer suppression, will inspire
new strategies for risk assessment and cancer prevention.
An example is provided by Hochberg et al.’s (this issue)
discussion of new strategies to limit or eradicate incipient
neoplasms by reducing microinflammation which may
spur neoplastic progression, and by reducing the accumula-
tion of DNA damage by administering poly ADP ribose
polymerase inhibitors.
In retrospect, it is remarkable that the evolution of cells
within tumors was not recognized until the 1970s with
Nowell’s (1976) paper ‘The clonal evolution of tumor cell
populations.’ Despite subsequent wide acceptance of evolu-
tionary explanations for cancer progression, applications of
evolutionary thinking remain limited; for instance, evolu-
tionary terms are used in only about 1% of the abstracts of
papers on therapeutic resistance (Aktipis et al. 2011).
While applications of evolutionary principles to the prob-
lems of cancer are in their infancy, they are growing fast, as
illustrated by many recent conferences across the world,
and the creation of two centers for the study of evolution
and cancer, the Center for Evolution and Cancer at the
University of California, San Francisco, and the Centre for
Ecological and Evolutionary Cancer Research at University
of Montpellier. We anticipate that evolutionary applica-
tions that advance cancer research and treatment will speed
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the growth of evolutionary medicine more generally, and
that as more physicians have opportunities to learn the
basic science of evolutionary biology, their insights will fur-
ther advance our understanding of cancer, as well as the
rest of medicine.
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